



Marksans Pharma Ltd.

July 08, 2022

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, Block -G
BandraKurla Complex
Bandra (East), Mumbai - 400 051

BSE Limited
Corporate Relationship Department
P.J. Towers, Dalal Street
Fort, Mumbai - 400 001

Reg.: Outcome of the Board Meeting held on July 08, 2022

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

With reference to our intimation letter dated July 4, 2022, we wish to inform you that the Board of Directors at its meeting held on July 08, 2022 has inter-alia approved the proposal to Buyback its own fully paid up Equity Shares of face value Re. 1/- each upto a maximum price of Rs. 60.00 (Indian Rupees Sixty only) per Equity Share ("**Maximum Buyback Price**") payable in cash for an aggregate Buyback consideration not exceeding Rs. 6000.00 Lakhs (Indian Rupees Six Thousand Lakhs only) ("**Maximum Offer Size**") which is 8.78% and 5.79% of the paid up share capital, free reserves and securities premium of the Company as per the latest audited standalone and consolidated financial statements of the Company, respectively, for the financial year ended March 31, 2022 through the Open Market route on the Stock Exchanges i.e., National Stock Exchange of India Limited ("**NSE**") and BSE Limited ("**BSE**") (NSE and BSE are collectively referred to as the "**Stock Exchanges**"), as prescribed under the SEBI (Buyback of Securities) Regulations, 2018 ("**SEBI Buyback Regulations**") and the Act (the process being referred herein as "**Buyback**") from the equity shareholders / beneficial owners of the Equity Shares of the Company (other than those who are promoters, members of the promoter group and persons in control of the Company).

The Maximum Buyback Size shall not include any expenses incurred or to be incurred for the Buyback like filing fees payable to the SEBI, merchant banker fees, stock exchange fee, transaction costs viz. brokerage, applicable taxes inter- alia including tax on distributed income to shareholders, Securities Transaction Tax, Goods and Services Tax, Stamp duty, etc., public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses

Subject to the market price of the Equity Share being equal to or less than the Maximum Buyback Price, the indicative maximum number of Equity Shares bought back would be 1,00,00,000 (One Crore) Equity Shares ("**Indicative Maximum Buyback Shares**"), comprising approximately 2.44% of the paid up Equity Share capital of the Company as of March 31, 2022. If the Equity Shares are bought back at a price below the Maximum Buyback Price, the actual number of Equity Shares bought back could exceed the Indicative Maximum Buyback Shares, but will always be subject to the Maximum Buyback Size and will not be exceed 25% of the paid-up Equity Share capital of the Company as at March 31, 2022. The Company shall utilise at least 50% of the amount earmarked as the Maximum Buyback Size for the Buyback i.e., Rs. 3000.00 Lakhs (Indian Rupees Three Thousand Lakhs only) ("**Minimum Buyback Size**"). Based on the Minimum Buyback Size and Maximum Buyback Price, the Company would purchase a minimum of 50,00,000 (Fifty Lakh) Equity Shares ("**Minimum Buyback Shares**").

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com

Marksans Pharma Ltd.

The Board also noted the Buyback being proposed to be undertaken through Stock Exchange route, the Promoter and Promoter Group and persons in control of the Company will not participate in the Buyback.

The pre-buyback summarised shareholding pattern of the Company is as under:

Shareholder	Pre-buyback		Post-Buyback	
	No. of Equity Shares	% of Equity Shares	No. of Equity Shares	% of Equity Shares
A. Promoter & Promoter Group	19,74,91,733	48.25	19,74,91,733	49.46
B. Public	21,18,21,965	51.75	20,18,21,965	50.54
C1. Shares underlying DRs	Nil	0.00	Nil	0.00
C2. Shares held by Employee Trust	Nil	0.00	Nil	0.00
C. Non-Promoter -Non-Public (C = C1+C2)	Nil	0.00	Nil	0.00
Grand Total (A+B+C)	40,93,13,698	100.00	39,93,13,698	100.00

#Assuming that the indicative Maximum Buyback Shares are bought back. However, the shareholding post completion of the Buyback, may differ depending upon the actual number of Equity Shares bought back in the Buyback.

The Board has constituted a Buyback Committee (the "Buyback Committee") comprising of below mentioned officials of the Company:

1. Mr. Mark Saldanha, Chairman and Managing Director
2. Mr. Jitendra Sharma, Chief Financial Officer
3. Mr. Harshavardhan Panigrahi, Company Secretary


The Buyback Committee has the power to do all such acts, deed and things and execute all documents, agreements, forms, certificates, undertakings and letters as may be necessary, usual, proper or expedient for the purpose of or in connection with the Buyback.

The meeting commenced at 6:00 p.m. and ended at 6:55 p.m.

We request you to kindly take the above intimation on your record.

Thanking you,

Yours faithfully,
for **Marksans Pharma Limited**



Harshavardhan Panigrahi
Company Secretary

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com